Table 1 Characteristics of included RCTs
Study | Year | Drug | Condition | Follow-up | Participants (N) | Women (%) (Treatment/Control) | Age, mean (SD), y | LVEF, mean (SD), % (Treatment/Control) | Primary outcomes |
|---|---|---|---|---|---|---|---|---|---|
DETERMINE-reduced | 2021 | dapagliflozin 10 mg | HFrEF | 16 weeks | 313 | 28.8%/23.3% | 67.8 ± 10.41 | NA | Change From Baseline in KCCQ-TSS, KCCQ-PLS and 6MWD |
DETERMINE-preserved | 2021 | dapagliflozin 10 mg | HFpEF | 16 weeks | 502 | 36%/37.1% | 71.8 ± 9.4 | NA | Change From Baseline in KCCQ-TSS, KCCQ-PLS and 6MWD |
PRESERVED-HF | 2022 | dapagliflozin 10 mg | HFpEF | 12 weeks | 324 | 56.8%/56.8% | 70(63 to77) | 60(55,65)/60(54,65) | Effect of Dapagliflozin, as Compared With Placebo, on Heart Failure Related Health Status Using the KCCQ-CS |
DEFINE-HF | 2022 | dapagliflozin 10 mg | HFrEF | 12 weeks | 263 | 27.5%/25.8% | 61.3 ± 11.5 | 27.2 ± 8.0/25.7 ± 8.2 | Mean NT-proBNP, proportion of patients with > 5 point increase on the KCCQ score |
EMPERIAL-Reduced | 2020 | empagliflozin 10 mg | HFrEF | 12 weeks | 311 | 22.4%/28.8% | 69.0 ± 10.2 | NA | Exercise Capacity as Measured by the 6MWT Distance |
EMPERIAL-perserved | 2020 | empagliflozin 10 mg | HFpEF | 12 weeks | 315 | 44.6%/41.8% | 73.5 ± 8.8 | NA | Exercise Capacity as Measured by the 6MWT Distance |
EMPEROR-Reduced | 2021 | empagliflozin 10 mg | HFrEF | 16 months | 3726 | 23.5%/24.4% | 66.8 ± 11.0 | 27.7 ± 6.0/27.2 ± 6.1 | Cardiovascular death or HHF |
EMPEROR-Preserved | 2022 | empagliflozin 10 mg | HFpEF | 1410 days | 5964 | 44.7%/44.6% | 71.9 ± 9.4 | 54.3 ± 8.8/54.3 ± 8.8 | Cardiovascular death or HHF |
DAPA-HF | 2020 | dapagliflozin 10 mg | HFrEF | 28.3 months | 4736 | 23.8%/23.0% | 66.3 ± 10.9 | 31.2 ± 6.7/30.9 ± 6.9 | Worsening of HF or death from cardiovascular causes |
SUGAR-DM-HF | 2020 | empagliflozin 10 mg | HFrEF | 36 weeks | 105 | 34.6%/18.9% | 68.7 ± 11.1 | 32.1 ± 10.3/32.9 ± 9.3 | Left ventricular end-systolic volume and global longitudinal strain |
DELIVER | 2023 | dapagliflozin 10 mg | HFpEF | 42.2 months | 6253 | 43.6%/44.2% | 71.7 ± 9.6 | 54.0 ± 8.6/54.3 ± 8.9 | An unplanned hospitalization for HF or an urgent visit for HF, or cardiovascular death |
SOLOIST-WHF | 2022 | sotagliflozin 200 mg | AHF | 21.9 months | 1216 | 32.6%/34.9% | 68.9 ± 9.1 | NA | Cardiovascular death or HHF |
EMPA-RESPONSE | 2020 | empagliflozin 10 mg | AHF | 60 days | 79 | 40%/25.6% | 76 (68 to 83) | NA | Dyspnea, diuretic, response length of stay and plasma NTproBNP |
CHIEF-HF | 2023 | canagliflozin 100 mg | HF | 12 weeks | 455 | 46.9%/42.9% | 63.4 ± 13.32 | NA | Change in Pulmonary Artery Diastolic Pressure |
EMBRACE-HF | 2021 | empagliflozin 10 mg | HF | 12 weeks | 65 | 36.4%/37.5% | 66.2 ± 12.9 | 46.7 ± 14.9/40.7 ± 17.2 | Change From Baseline in KCCQ-TSS |
EMPULSE | 2022 | empagliflozin 10 mg | AHF | 127 days | 524 | 35.1%/32.5% | 68.5 ± 13.2 | NA | Percentage of Pairwise Comparisons With Wins of Clinical Benefit, a Composite of Death, Number of HFEs, Time to the First HFE and ≥ 5-point Difference in CfB in KCCQ-TSS |